Guggenheim Capital LLC Sage Therapeutics, Inc. Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

A detailed history of Guggenheim Capital LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 48,764 shares of SAGE stock, worth $265,276. This represents 0.0% of its overall portfolio holdings.

Number of Shares

48,764

Previous 36,216 34.65%

Holding current value

$265,276

Previous $393,000 10.69%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$7.02 - $13.08 $88,086 - $164,127	12,548 Added 34.65%	48,764 $351,000
Q2 2024 Aug 14, 2024	BUY	$10.58 - $17.9 $61,099 - $103,372	5,775 Added 18.97%	36,216 $393,000
Q1 2024 May 14, 2024	BUY	$18.62 - $26.95 $14,598 - $21,128	784 Added 2.64%	30,441 $570,000
Q4 2023 Feb 14, 2024	BUY	$17.1 - $22.26 $507,134 - $660,164	29,657 New	29,657 $642,000
Q3 2022 Nov 14, 2022	SELL	$32.28 - $43.27 $20,304 - $27,216	-629 Reduced 5.11%	11,674 $457,000
Q2 2022 Aug 15, 2022	BUY	$27.52 - $37.99 $7,815 - $10,789	284 Added 2.36%	12,303 $397,000
Q1 2022 May 16, 2022	BUY	$30.71 - $45.71 $1,320 - $1,965	43 Added 0.36%	12,019 $398,000
Q4 2021 Feb 14, 2022	SELL	$37.06 - $47.11 $1.52 Million - $1.93 Million	-41,018 Reduced 77.4%	11,976 $509,000
Q3 2021 Nov 15, 2021	BUY	$40.26 - $57.37 $428,406 - $610,474	10,641 Added 25.12%	52,994 $2.35 Million
Q2 2021 Aug 13, 2021	BUY	$54.88 - $79.29 $226,050 - $326,595	4,119 Added 10.77%	42,353 $2.41 Million
Q1 2021 May 13, 2021	BUY	$70.65 - $96.76 $408,992 - $560,143	5,789 Added 17.84%	38,234 $2.86 Million
Q4 2020 Feb 16, 2021	BUY	$58.41 - $89.06 $488,190 - $744,363	8,358 Added 34.7%	32,445 $2.81 Million
Q3 2019 Nov 14, 2019	SELL	$140.29 - $189.96 $195,423 - $264,614	-1,393 Reduced 5.47%	24,087 $3.38 Million
Q2 2019 Aug 14, 2019	SELL	$157.85 - $183.09 $1.03 Million - $1.2 Million	-6,531 Reduced 20.4%	25,480 $4.67 Million
Q1 2019 May 15, 2019	SELL	$89.33 - $163.65 $485,240 - $888,946	-5,432 Reduced 14.51%	32,011 $5.09 Million
Q4 2018 Feb 14, 2019	BUY	$81.94 - $139.71 $335,380 - $571,833	4,093 Added 12.27%	37,443 $3.59 Million
Q3 2018 Nov 14, 2018	BUY	$138.11 - $169.04 $180,924 - $221,442	1,310 Added 4.09%	33,350 $4.71 Million
Q2 2018 Aug 14, 2018	SELL	$140.36 - $175.76 $883,987 - $1.11 Million	-6,298 Reduced 16.43%	32,040 $5.02 Million
Q1 2018 May 15, 2018	BUY	$152.15 - $192.33 $20,235 - $25,579	133 Added 0.35%	38,338 $6.18 Million
Q4 2017 Feb 14, 2018	SELL	$60.72 - $167.34 $2.79 Million - $7.68 Million	-45,883 Reduced 54.57%	38,205 $6.29 Million
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $5.16 Million - $7.44 Million	84,088	84,088 $5.24 Million

Others Institutions Holding SAGE

# of Institutions

198

Shares Held

46.5M

Call Options Held

402K

Put Options Held

209K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Sage Therapeutics, Inc. Transaction History